Diagnostic markers for glioblastoma
Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation and chemotherapy, the prognosis of patients with GBM is still very poor. In the past decades knowledge of genomics and proteomics and of diagnostic, prognostic, predictiv...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2011
|
| In: |
Histology and histopathology
Year: 2011, Volume: 26, Issue: 10, Pages: 1327-1341 |
| ISSN: | 1699-5848 |
| DOI: | 10.14670/HH-26.1327 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: http://dx.doi.org/10.14670/HH-26.1327
|
| Author Notes: | C.S. Jung, A.W. Unterberg and C. Hartmann |
| Summary: | Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation and chemotherapy, the prognosis of patients with GBM is still very poor. In the past decades knowledge of genomics and proteomics and of diagnostic, prognostic, predictive and pharmakodynamic markers measured in cerebrospinal-fluid (CSF), serum, or tumor tissue biomarkers has improved. This review briefly compiles our concepts on diagnostic markers for GBM, focusing on the latest developments |
|---|---|
| Item Description: | Gesehen am 05.07.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1699-5848 |
| DOI: | 10.14670/HH-26.1327 |